DE-127 Ophthalmic Solution low dose + DE-127 Ophthalmic Solution medium dose + DE-127 Ophthalmic Solution high dose + Placebo Ophthalmic Solution
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout DE-127 Ophthalmic Solution low dose + DE-127 Ophthalmic Solution medium dose + DE-127 Ophthalmic Solution high dose + Placebo Ophthalmic Solution
DE-127 Ophthalmic Solution low dose + DE-127 Ophthalmic Solution medium dose + DE-127 Ophthalmic Solution high dose + Placebo Ophthalmic Solution is a phase 2 stage product being developed by Santen Pharmaceutical for Myopia. The current trial status is completed. This product is registered under clinical trial identifier NCT03329638. Target conditions include Myopia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03329638 | Phase 2 | Completed |
Competing Products
5 competing products in Myopia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 77 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 76 |
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77